According to a report on the British “Nature” website on the 22nd, the American biotech company Pioneer Pharmaceuticals announced that it has used pilot editing technology to directly edit DNA in the human body for the first time to treat a Wilson disease patient. The first batch of clinical trial results is expected to be announced in 2027.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.